The ornithine decarboxylase 1 (ODC1) gene, for the first time in humans, has been linked to a new pediatric disorder leading to macrosomia, macrocephaly, developmental delays, alopecia, hypotonia, and hearing loss, according to a new report.
The ornithine decarboxylase 1 (ODC1) gene, for the first time in humans, has been linked to a new pediatric disorder leading to macrosomia, macrocephaly, developmental delays, alopecia, hypotonia, and hearing loss, according to a report by Bupp et al.
ODC1 mutations associated with overexpressing c-terminally deleted ODC was described over 20 years ago in mouse models as a cause of higher polyamine (PA) biosynthesis, which plays an important role in cell developmental processes such as embryogenesis, organogenesis, and neoplastic cell growth. At the Helene DeVos Children’s Hospital, a 32-month-old female patient had sanger sequencing testing done, confirming the ODC1 variant mutation. The ODC1 mutation identified led to the deletion of the c-terminal 14 amino acid of the ODC protein and subsequently an increase in ODC protein accumulation.
Read more about rare diseases.
At 11 months, developmental delays began to become apparent, starting with poor neck control. At 30 months, the patient remained nonverbal, making only cooing noises and occasional sound imitations. The patient was unable to sit by herself and did not have pincer grasp when reaching for objects. Spasticity in the lower extremities, nighttime eye deviation and tonic limb deviations were also observed. A direct assessment of her eyes found esotropia, bilateral myopic astigmatism, and pseudostrabismus. Nails were brittle and extremely curved, and white matter volume loss was evident on a magnetic resonance imaging (MRI) in both cerebral hemispheres. Wound healing was normal, but the patient had an unusually high tolerance for pain.
Previous studies had already identified that the c-terminal 37 amino acid of ODC led to higher ODC enzyme activity. In mice with this mutation, ODC protein and PA levels were both increased, leading to multiple hair and skin abnormalities including alopecia. In this patient, similar increases in ODC protein and PA levels were also seen. The higher PA level was also associated with increased putrescine, an amine produced when ornithine is enzymatically converted by ODC. Eflornithine (DFMO), a drug approved for use in the treatment of trypanosomiasis (African sleeping sickness), leads to putrescine production inhibition, preventing hair loss, and restoring hair growth in mice.
The use of DFMO may be justified “since some developmental delays are not likely reversible after the child has reached a certain age” said André Bachmann, a professor of pediatrics in the MSU College of Human Medicine in a news release from Michigan State University.
Bupp et al has identified the first human case of c-terminal ODC1deletion that has presented itself as a developmental disorder. DFMO is theorized as a possible therapeutic agent that can prevent neurologic deterioration and developmental delays early in the disease. Screenings for ODC1 mutations when these symptoms are present may be useful to catch and intervene other cases discovered in the future.
Reference
Bupp CP, Schultz CR, Uhi KL, Rajasekaran S, Bachmann AS. Novel de novo pathogenic variant in the ODC1 gene in a girl with developmental delay, alopecia, and dysmorphic features [published online September 21, 2018]. Am J Med Genet A.doi: 10.1002/ajmg.a.40523.
The observed patient was born at 37 weeks by cesarean section and was sent to neonatal intensive care for 35 days due to hypotonia, hypoglycemia, feeding difficulties, and hyperbilirubinemia. The patient failed the newborn hearing screen and was diagnosed with right-sided sensorineural hearing loss. Hair loss was evident almost immediately; the hair that she was born with fell out during the first month of life, and she had no eyebrows and few eyelashes.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen